results
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories) reported zero revenue from operations for both Q3 FY26 and the nine months ended December 2025, with only Rs 4.77 lakhs of other income for the period. The company posted a loss after tax of Rs 22.03 lakhs in Q3 and Rs 66.06 lakhs for 9M FY26, slightly wider than the Rs 61.83 lakhs loss in 9M FY25. Manufacturing operations remain halted pending renewal of its Drug Manufacturing Licence from the FDA in Panchkula, and the company has negative net worth of Rs (1,803.07) lakhs. BSE listing fees have not been paid since FY 2021-22, restricting trading to one day per week on a Trade-for-Trade basis. The statutory auditor issued a qualified conclusion, flagging unverified investments of Rs 53.80 lakhs, stalled capital work-in-progress of Rs 2.49 crore, and emphasis of matter on the absence of operating revenue.
Persistent operational shutdown, mounting quarterly losses, and deeply negative net worth raise serious going-concern doubts. Shareholders face heightened risk as the stock already trades on a restrictive Trade-for-Trade basis and any meaningful recovery hinges on FDA license renewal and management's ability to restart manufacturing.